Investing.com - Financial Markets Worldwide

IX Biopharma Ltd (IXBI)

Singapore
Currency in SGD
0.020
0.000(0.00%)
Closed·
IXBI Scorecard
Full Analysis
Quickly burning through cash
IXBI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
0.0200.020
52 wk Range
0.0150.029
Key Statistics
Edit
Bid/Ask
0.02 / 0.021
Prev. Close
0.02
Open
0.02
Day's Range
0.02-0.02
52 wk Range
0.015-0.029
Volume
94.6K
Average Volume (3m)
420.88K
1-Year Change
-28.57%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IXBI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 5
Short term obligations exceed liquid assets
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

IX Biopharma Ltd Company Profile

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, and insomnia. The company is also developing Wafermine, a racemic ketamine sublingual wafer, which has completed phase-2 clinical trial for the treatment of complex regional pain syndrome, as well as psychiatric conditions, including depression; iXB 401, a sublingual semaglutide wafer that is in pre-clinical development for the treatment of Type 2 Diabetes and Obesity; SL-NAD+, a sublingual NAD+ wafer to increase the body’s NAD+ levels, energy levels, and alertness; iXB 120 that has completed Phase I clinical trial for acute agitation; IXB-214, which has completed Phase I clinical trial for complex regional pain syndrome; and IXB-314 that has completed Phase I clinical trial for treatment resistant depression. In addition, it develops BnoX that is in a phase-1 clinical trial for moderate to severe pain; NAD+ for sarcopenia; iXB 321, an influenza vaccine; iXB 322, a novel low-dose interferon sublingual wafe for respiratory viral prophylaxis; and LumeniX, a sublingual glutathione wafer for skin brightening and immunity. iX Biopharma Ltd. was incorporated in 2004 and is headquartered in Singapore.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
42
Market
Singapore

Compare IXBI to Peers and Sector

Metrics to compare
IXBI
Peers
Sector
Relationship
P/E Ratio
−1.8x2.3x−0.5x
PEG Ratio
−0.310.060.00
Price/Book
5.1x1.4x2.6x
Price / LTM Sales
2.5x1.7x3.2x
Upside (Analyst Target)
-27.9%41.7%
Fair Value Upside
Unlock3.0%6.1%Unlock

Earnings

Latest Release
Feb 07, 2025
EPS / Forecast
-0.01 / --
Revenue / Forecast
3.71M / --
EPS Revisions
a
a
Unlock
Last 90 days

IXBI Income Statement

FAQ

What Stock Exchange Does IX Biopharma Ltd Trade On?

IX Biopharma Ltd is listed and trades on the Singapore Stock Exchange stock exchange.

What Is the Stock Symbol for IX Biopharma Ltd?

The stock symbol for IX Biopharma Ltd is "IXBI."

What Is the IX Biopharma Ltd Market Cap?

As of today, IX Biopharma Ltd market cap is 17.76M.

What Is IX Biopharma Ltd's Earnings Per Share (TTM)?

The IX Biopharma Ltd EPS (TTM) is -0.01.

From a Technical Analysis Perspective, Is IXBI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has IX Biopharma Ltd Stock Split?

IX Biopharma Ltd has split 3 times.

How Many Employees Does IX Biopharma Ltd Have?

IX Biopharma Ltd has 42 employees.

What is the current trading status of IX Biopharma Ltd (IXBI)?

As of 26 Jul 2025, IX Biopharma Ltd (IXBI) is trading at a price of 0.02, with a previous close of 0.02. The stock has fluctuated within a day range of 0.02 to 0.02, while its 52-week range spans from 0.02 to 0.03.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.